

# People

## Appointments

### Michael E. Raymer named Senior Vice President and General Manager, IDX Carecast

IDX Systems Corporation (<http://www.idx.com>) has announced the promotion of Michael E. Raymer to Senior Vice President and General Manager of the company's Carecast Operating Unit. Raymer joined IDX in 2001 and has been responsible for Carecast's product strategy and market development. He brings 20 years of management expertise in the clinical software industry to his current position.

'Mike has been a key member of the management team that has led Carecast's recent successes in the marketplace,' said James H. Crook Jr, CEO of IDX.

Prior to joining IDX, Raymer served as VP at Shared Healthcare Systems. He succeeds Larry Krassner, who has resigned from his position as leader of Carecast to pursue other interests.

Founded in 1969, IDX Systems Corporation provides information technology solutions to maximize value in the delivery of healthcare, improve the quality of patient service, enhance medical outcomes, and reduce the costs of care.

### NextGen appoints Andrew Creasey as President

NextGen Sciences (<http://www.nextgensciences.com>), based in Huntingdon, UK, has announced the formation of its first international office, in Bedford, MA, USA. Leading the operation will be their newly appointed President, Andrew Creasey.

Kevin A. Auton, CEO of NextGen Sciences, said: 'Creasey's knowledge of biotechnology and protein research will prove invaluable to the company as we begin to commercialize our cutting-edge technologies outside of Europe.'

Creasey has more than 20 years experience in sales management, marketing, operations and product development in the life sciences sector. He was most recently Director of Marketing at Harvard Bioscience.

On his appointment, Creasey said: 'I have followed the progress of NextGen Sciences since it was founded three years

ago and was very impressed with their creativity and commitment to solving problems in protein research.'

### Mitchell Seyedin joins Isto Technologies as President and CEO

Isto Technologies (<http://www.istotech.com>) have announced the appointment of Mitchell Seyedin, to succeed Joseph Feder, as President and Chief Executive Officer. Most recently, Seyedin was co-founder, President and CEO of CBYON.

Feder comments: 'Dr Seyedin will lead the Company through its next phase of growth and the commercialization of our proprietary cartilage and bone regeneration technology platforms. We are very pleased that an industry veteran with Dr Seyedin's credentials and background has joined the Isto team.'

Isto Technologies is an emerging biotechnology company that is developing therapeutics for the repair, replacement and regeneration of musculoskeletal tissue.

### Medical Director appointed at Microscience

John St Clair Roberts has been appointed Medical Director of Microscience (<http://www.microscience.com>). St Clair Roberts has nearly 20 years experience in clinical development of novel vaccines for infectious diseases.

Prior to this new appointment at Microscience, St Clair Roberts was Medical Director at Xenova, before which he was with Cantab, and from 1986-1994 he held several senior medical management positions with Merieux, following an early medical career with the NHS.

Welcoming St Clair Roberts to the company, Chief Executive Officer, Rod Richards, said: John's breadth of experience will be extremely valuable to the company as we develop multiple products in the clinic and deliver a broad portfolio of high value, high quality vaccines.'

Microscience is a UK-based biotechnology company that focuses on vaccine discovery and development.

### Xantos Biomedicine announces new CEO

Xantos Biomedicine (<http://www.xantos.de>) has announced the promotion of Stephan

Wehselau to CEO, effective from 1 October 2003. Wehselau will also serve on the Board of Directors with immediate effect.

Commenting on his promotion, Wehselau said: 'Having been with the company since its inception, I helped steer its transition from a functional genomics technology company into one that is successfully using its platform to generate products. I look forward to leading the company in its next stage of development...'

Wehselau is a co-founder of Xantos, a leading functional biology and drug discovery company developing biopharmaceuticals in the areas of cancer and metabolic, inflammatory and degenerative diseases.

Paul Nicholson, Chairman of the Supervisory Board, said: 'Stephan's skills are those which are appropriate to lead the next stage in the growth of Xantos.'

## Awards

### Lasker award goes to pioneer of gene activation studies

Robert G. Roeder is this year's recipient of the highly prestigious Albert Lasker Award for Basic Medical Research, as announced by the Albert and Mary Lasker Foundation.

Roeder is a biochemist whose research has led to major advances in understanding how human genes are switched on and off. Since 1969, when he made his initial groundbreaking discovery of the three protein machines that are responsible for reading human genes, Roeder has elucidated the manner in which this process is orchestrated.

Rockefeller University President Paul Nurse said: 'Virtually all of what we know about gene activation and its regulation in animal cells can be traced back to Bob Roeder's seminal studies.'

Roeder, the Arnold and Mabel Beckman Professor and Head of the Laboratory of Molecular Biology and Biochemistry at Rockefeller University (<http://www.rockefeller.edu>), said: 'We need to understand not only the mechanisms underlying normal gene activation, but to relate these to important medical problems. As we become familiar with the fundamentals of how genes work, we get closer to understanding diseases like cancer, or viral infections such as HIV.'

People was written by  
*Steve Carney and Joanne Clough*